HK1177465A1 - 具有延長的體內半衰期的生理學活性多肽綴合物 - Google Patents

具有延長的體內半衰期的生理學活性多肽綴合物

Info

Publication number
HK1177465A1
HK1177465A1 HK13102067.9A HK13102067A HK1177465A1 HK 1177465 A1 HK1177465 A1 HK 1177465A1 HK 13102067 A HK13102067 A HK 13102067A HK 1177465 A1 HK1177465 A1 HK 1177465A1
Authority
HK
Hong Kong
Prior art keywords
life
prolonged
physiologically active
active polypeptide
vivo half
Prior art date
Application number
HK13102067.9A
Other languages
English (en)
Inventor
金榮民
金大振
裴城敏
林昌基
權世昌
李寬淳
Original Assignee
韓美科學株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 韓美科學株式會社 filed Critical 韓美科學株式會社
Publication of HK1177465A1 publication Critical patent/HK1177465A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK13102067.9A 2003-03-13 2013-02-19 具有延長的體內半衰期的生理學活性多肽綴合物 HK1177465A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030015744 2003-03-13
KR20030036408 2003-06-05

Publications (1)

Publication Number Publication Date
HK1177465A1 true HK1177465A1 (zh) 2013-08-23

Family

ID=36096009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13102067.9A HK1177465A1 (zh) 2003-03-13 2013-02-19 具有延長的體內半衰期的生理學活性多肽綴合物

Country Status (16)

Country Link
US (2) US20050176108A1 (zh)
EP (1) EP1601698B1 (zh)
JP (1) JP4481980B2 (zh)
KR (1) KR100567902B1 (zh)
CN (2) CN102757505B (zh)
AT (1) ATE425188T1 (zh)
AU (1) AU2004220163B2 (zh)
BR (1) BRPI0408331B8 (zh)
CA (1) CA2519059C (zh)
DE (1) DE602004019887D1 (zh)
ES (1) ES2324298T3 (zh)
HK (1) HK1177465A1 (zh)
IL (1) IL170685A (zh)
PT (1) PT1601698E (zh)
RU (1) RU2312868C2 (zh)
WO (1) WO2004081053A1 (zh)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
ES2372495T3 (es) * 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
NO20210454A1 (no) * 2004-11-12 2007-06-27 Bayer Healthcare Llc Setedirigert modifikasjon av FVIII
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1877101B1 (en) * 2005-04-28 2016-11-16 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
CN101184771A (zh) * 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007049940A1 (en) * 2005-10-27 2007-05-03 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
DK1951316T3 (en) 2005-11-23 2015-08-31 Ventana Med Syst Inc molecular conjugate
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP2010530222A (ja) * 2007-06-06 2010-09-09 べーリンガー インゲルハイム インターナショナル ゲーエムベーハー ナトリウム利尿融合タンパク質
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
WO2010074082A1 (ja) * 2008-12-24 2010-07-01 塩野義製薬株式会社 バソヒビン修飾体
CN101585864B (zh) * 2009-01-05 2011-11-09 天津派格生物技术有限公司 柱层析粒细胞集落刺激因子氮端定点偶联方法及其产物
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
RU2495881C2 (ru) * 2009-03-20 2013-10-20 Ханми Холдингс Ко., Лтд. Способ регулирования условий для сайт-специфического связывания полипептида и непептидильного полимера
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
RU2519031C1 (ru) * 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Жидкие препаративные формы для длительно действующего конъюгата g-csf
MX2012008453A (es) * 2010-01-19 2012-11-21 Hanmi Science Co Ltd Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada.
US20120328589A1 (en) * 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
RU2013127786A (ru) * 2010-11-19 2014-12-27 Венус Ремедиз Лимитед Новые конъюгаты для направленной доставки лекарственного средства
KR101309566B1 (ko) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
AU2011356137A1 (en) 2011-01-20 2013-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
CN102309765B (zh) * 2011-02-28 2013-10-16 北京韩美药品有限公司 包含免疫球蛋白Fc片段作为载体的长效抗凝多肽及其制备方法
RU2502803C2 (ru) * 2011-05-20 2013-12-27 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia, НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНОВ, БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТОВ ПОЛИЭТИЛЕНГЛИКОЛЯ И РЕКОМБИНАНТНОГО МУТЕИНА ДНКазы I ЧЕЛОВЕКА, ФЕРМЕНТАТИВНО АКТИВНЫЙ КОНЪЮГАТ МУТЕИНА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102807619B (zh) * 2011-06-03 2016-08-03 北京韩美药品有限公司 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物
CN102313773B (zh) * 2011-07-29 2013-11-20 首都师范大学 一种鉴定蛋白质中半胱氨酸数量的方法及其应用
CN103611163A (zh) * 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103235136B (zh) * 2012-04-28 2014-12-10 淄博高新区云桥生物技术研究所 蛋白质类药物三维构像的抗体阵序列检测方法
WO2013183948A1 (ko) * 2012-06-05 2013-12-12 씨제이제일제당 (주) 고당화된 지속형 인간 성장호르몬 단백질 및 이의 제조방법
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
EA034499B1 (ru) 2012-11-06 2020-02-13 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
RU2683823C2 (ru) 2013-09-27 2019-04-02 Ханми Фарм. Ко., Лтд. Препарат гормона роста человека длительного типа
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
MA43289B1 (fr) * 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016149562A2 (en) * 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
RU2656140C2 (ru) * 2016-11-14 2018-05-31 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Способ получения гибридного белка, состоящего из рекомбинантного белка аналога интерферона гамма, конъюгированного с олигосахаридом
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. PERSISTENT PROTEIN CONJUGATE WITH IMPROVED EFFICIENCY
CN108164700B (zh) * 2017-12-27 2020-05-08 暨南大学 一种用于输送疏水性药物的活性氧响应性纳米载体及其制备方法
GB201801902D0 (en) * 2018-02-06 2018-03-21 Stichting Katholieke Univ Immunomodulatory nanofilaments
KR101974305B1 (ko) * 2018-02-14 2019-04-30 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
JP2021066730A (ja) * 2019-10-17 2021-04-30 Ｊｃｒファーマ株式会社 血清アルブミンと成長ホルモンの融合蛋白質の製造方法
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2021261712A1 (en) * 2020-06-26 2021-12-30 Sunbio, Inc. Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
US4487325A (en) 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
GB8504099D0 (en) * 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
KR0172969B1 (ko) * 1991-04-17 1999-02-01 삐에르 까스뗄 인터페론 알파 및 베타에 대해 높은 친화력을 갖는 수용성 폴리펩티드
CA2120023A1 (en) * 1992-07-28 1994-02-03 Noriaki Uenishi Immunoconjugate
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
WO2001003737A1 (en) 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2001023430A2 (en) * 1999-09-30 2001-04-05 Icos Corporation Human chitinase immunoglobulin fusion proteins
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
WO2004024889A2 (en) 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives

Also Published As

Publication number Publication date
EP1601698B1 (en) 2009-03-11
KR20040081378A (ko) 2004-09-21
KR100567902B1 (ko) 2006-04-04
AU2004220163A1 (en) 2004-09-23
EP1601698A1 (en) 2005-12-07
US20050176108A1 (en) 2005-08-11
JP4481980B2 (ja) 2010-06-16
RU2312868C2 (ru) 2007-12-20
CA2519059A1 (en) 2004-09-23
BRPI0408331A (pt) 2006-03-21
WO2004081053A1 (en) 2004-09-23
PT1601698E (pt) 2009-06-17
JP2007528346A (ja) 2007-10-11
BRPI0408331A8 (pt) 2016-06-07
ATE425188T1 (de) 2009-03-15
CN102757505A (zh) 2012-10-31
DE602004019887D1 (de) 2009-04-23
US20100105869A1 (en) 2010-04-29
EP1601698A4 (en) 2006-05-03
CA2519059C (en) 2012-12-18
IL170685A (en) 2012-05-31
CN1761684A (zh) 2006-04-19
CN102757505B (zh) 2015-10-07
IL170685A0 (en) 2009-02-11
AU2004220163B2 (en) 2008-01-31
RU2005128504A (ru) 2006-03-10
BRPI0408331B1 (pt) 2019-09-17
US8163889B2 (en) 2012-04-24
ES2324298T3 (es) 2009-08-04
BRPI0408331B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1177465A1 (zh) 具有延長的體內半衰期的生理學活性多肽綴合物
MXPA05007210A (es) Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
DE60039629D1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
TNSN00206A1 (en) Method for treating diabetes
MXPA05013564A (es) Proteinas de fusion.
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
DE60109949D1 (de) Chirurgischer kopfrahmen mit weichen kontaktauflagen für stereotaktisches system
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
DE69804974T2 (de) Opioid-konjugate mit endogenen trägerproteinen
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
AU2003207417A1 (en) Use of tryptophan rich peptides
NO20042055L (no) Tymosinalfa 1-peptid/polymerkonjugater
SE9703775D0 (sv) Solution for peritoneal dialysis and process for its manufacture
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
CA2373252A1 (en) Long lasting anti-angiogenic peptides
Smits et al. Acute effects of flosequinan (BTS 49465) in untreated moderate to severe hypertension
MD1474F1 (en) Method of treatment of the puerperal endometritis
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240312